Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allergan Hopes To Add Bipolar Depression To Vraylar's Label

Executive Summary

With Phase III success in bipolar depression, Allergan plans an sNDA in 2018 to add that indication to the atypical antipsychotic's label, which includes schizophrenia and bipolar mixed or manic episodes.

You may also be interested in...



Pharma Q4 Results Preview: Bristol, Allergan, Gilead, GSK, Sanofi, Teva

Hemophilia and immuno-oncology will be in the spotlight as earnings season continues into February. Will Bristol be a buyer or an acquisition target? How will Sanofi fare with its new acquisitions? And how will Teva and GSK fare as they face generics for top brands?

Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow

Allergan will spend 2018 trying to shift investor focus from the loss of Restasis patent exclusivity in the second half of the year to the company's R&D pipeline, including the late-stage "six stars" highlighted in 2017 and mid-stage programs that are moving into the spotlight.

Allergan Readies Cost Cuts As Restasis Generics Approach

Allergan is working on a plan to reduce costs now that Restasis generics could hit the US market in 2018, but the company said sales growth for other drugs coupled with new product launches will boost revenue even if the dry eye drug loses its blockbuster status.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel